Overview

Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This is a safety, tolerability and pharmacokinetics study of AGN-190168 in subjects with acne vulgaris.
Phase:
Phase 1
Details
Lead Sponsor:
Allergan
Treatments:
Nicotinic Acids
Tazarotene